On Tuesday, Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) opened higher 2.33% from the last session, before settling in for the closing price of $11.59. Price fluctuations for ARCT have ranged from $8.04 to $45.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 301.31% over the past five years. Company’s average yearly earnings per share was noted -22.28% at the time writing. With a float of $24.37 million, this company’s outstanding shares have now reached $27.12 million.
Let’s look at the performance matrix of the company that is accounted for 176 employees. In terms of profitability, gross margin is 79.11%, operating margin of -47.08%, and the pretax margin is -50.73%.
Arcturus Therapeutics Holdings Inc (ARCT) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Arcturus Therapeutics Holdings Inc is 10.14%, while institutional ownership is 88.26%. The most recent insider transaction that took place on Oct 15 ’24, was worth 249,121. In this transaction Chief Scientific Officer & COO of this company sold 12,000 shares at a rate of $20.76, taking the stock ownership to the 435,334 shares. Before that another transaction happened on Oct 15 ’24, when Company’s Officer proposed sale 12,000 for $20.76, making the entire transaction worth $249,121.
Arcturus Therapeutics Holdings Inc (ARCT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -22.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 74.10% during the next five years compared to -6.84% drop over the previous five years of trading.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Trading Performance Indicators
Check out the current performance indicators for Arcturus Therapeutics Holdings Inc (ARCT). In the past quarter, the stock posted a quick ratio of 5.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.52, a number that is poised to hit -0.99 in the next quarter and is forecasted to reach -3.04 in one year’s time.
Technical Analysis of Arcturus Therapeutics Holdings Inc (ARCT)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) saw its 5-day average volume 0.52 million, a positive change from its year-to-date volume of 0.43 million. As of the previous 9 days, the stock’s Stochastic %D was 27.88%. Additionally, its Average True Range was 1.03.
During the past 100 days, Arcturus Therapeutics Holdings Inc’s (ARCT) raw stochastic average was set at 28.90%, which indicates a significant decrease from 35.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.49% in the past 14 days, which was lower than the 74.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.06, while its 200-day Moving Average is $17.22. Nevertheless, the first resistance level for the watch stands at $13.30 in the near term. At $14.74, the stock is likely to face the second major resistance level. The third major resistance level sits at $15.53. If the price goes on to break the first support level at $11.07, it is likely to go to the next support level at $10.28. The third support level lies at $8.84 if the price breaches the second support level.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Key Stats
There are currently 27,121K shares outstanding in the company with a market cap of 321.65 million. Presently, the company’s annual sales total 152,310 K according to its annual income of -80,940 K. Last quarter, the company’s sales amounted to 22,770 K and its income totaled -30,010 K.
